Mr. Engel (for
himself, Mr. Burgess,
Mr. King of New York,
Ms. McCollum, and
Ms. Pingree of Maine) introduced the
following bill; which was referred to the Committee on Energy and
Commerce

A BILL

To provide grants to better understand and reduce
gestational diabetes, and for other purposes.

1.

Short title

This Act may be cited as the
Gestational Diabetes Act of
2013 or the GEDI
Act.

2.

Gestational
diabetes

Part B of title III
of the Public Health Service Act (42 U.S.C. 243 et seq.) is amended by
inserting after section 317H the following:

317H–1.

Gestational
diabetes

(a)

Understanding
and monitoring gestational diabetes

(1)

In
general

The Secretary, acting through the Director of the Centers
for Disease Control and Prevention, in consultation with the Diabetes Mellitus
Interagency Coordinating Committee established under section 429 and
representatives of appropriate national health organizations, shall develop a
multisite gestational diabetes research project within the diabetes program of
the Centers for Disease Control and Prevention to expand and enhance
surveillance data and public health research on gestational diabetes.

(2)

Areas to be
addressed

The research project developed under paragraph (1)
shall address—

(A)

procedures to
establish accurate and efficient systems for the collection of gestational
diabetes data within each State and commonwealth, territory, or possession of
the United States;

(B)

the progress of
collaborative activities with the National Vital Statistics System, the
National Center for Health Statistics, and State health departments with
respect to the standard birth certificate, in order to improve surveillance of
gestational diabetes;

(C)

postpartum methods of tracking women with
gestational diabetes after delivery as well as targeted interventions proven to
lower the incidence of type 2 diabetes in that population;

(D)

variations in the
distribution of diagnosed and undiagnosed gestational diabetes, and of impaired
fasting glucose tolerance and impaired fasting glucose, within and among groups
of women; and

Not
later than 2 years after the date of the enactment of this section, and
annually thereafter, the Secretary shall generate a report on the findings and
recommendations of the research project including prevalence of gestational
diabetes in the multisite area and disseminate the report to the appropriate
Federal and non-Federal agencies.

(b)

Expansion of
gestational diabetes research

(1)

In
General

The Secretary shall
expand and intensify public health research regarding gestational diabetes.
Such research may include—

(A)

developing and
testing novel approaches for improving postpartum diabetes testing or screening
and for preventing type 2 diabetes in women with a history of gestational
diabetes; and

(B)

conducting public
health research to further understanding of the epidemiologic,
socioenvironmental, behavioral, translation, and biomedical factors and health
systems that influence the risk of gestational diabetes and the development of
type 2 diabetes in women with a history of gestational diabetes.

(2)

Authorization of
Appropriations

There is authorized to be appropriated to carry
out this subsection$5,000,000 for each of fiscal years 2014 through
2018.

(c)

Demonstration
grants To lower the rate of gestational diabetes

(1)

In
General

The Secretary, acting
through the Director of the Centers for Disease Control and Prevention, shall
award grants, on a competitive basis, to eligible entities for demonstration
projects that implement evidence-based interventions to reduce the incidence of
gestational diabetes, the recurrence of gestational diabetes in subsequent
pregnancies, and the development of type 2 diabetes in women with a history of
gestational diabetes.

(2)

Priority

In
making grants under this subsection, the Secretary shall give priority to
projects focusing on—

(A)

helping women who have one or more risk
factors for developing gestational diabetes;

(B)

working with women with a history of
gestational diabetes during a previous pregnancy;

(C)

providing postpartum care for women with
gestational diabetes;

(D)

tracking cases where women with a history
of gestational diabetes developed type 2 diabetes;

(E)

educating mothers with a history of
gestational diabetes about the increased risk of their child developing
diabetes;

(F)

working to prevent gestational diabetes and
prevent or delay the development of type 2 diabetes in women with a history of
gestational diabetes; and

(G)

achieving outcomes designed to assess the
efficacy and cost-effectiveness of interventions that can inform decisions on
long-term sustainability, including third-party reimbursement.

(3)

Application

An
eligible entity desiring to receive a grant under this subsection shall submit
to the Secretary—

(A)

an application at
such time, in such manner, and containing such information as the Secretary may
require; and

(B)

a plan to—

(i)

lower the rate of
gestational diabetes during pregnancy; or

(ii)

develop methods of tracking women with a
history of gestational diabetes and develop effective interventions to lower
the incidence of the recurrence of gestational diabetes in subsequent
pregnancies and the development of type 2 diabetes.

(4)

Uses of
Funds

An eligible entity receiving a grant under this subsection
shall use the grant funds to carry out demonstration projects described in
paragraph (1), including—

(A)

expanding
community-based health promotion education, activities, and incentives focused
on the prevention of gestational diabetes and development of type 2 diabetes in
women with a history of gestational diabetes;

(B)

aiding State- and tribal-based diabetes
prevention and control programs to collect, analyze, disseminate, and report
surveillance data on women with, and at risk for, gestational diabetes, the
recurrence of gestational diabetes in subsequent pregnancies, and, for women
with a history of gestational diabetes, the development of type 2 diabetes;
and

(C)

training and
encouraging health care providers—

(i)

to
promote risk assessment, high-quality care, and self-management for gestational
diabetes and the recurrence of gestational diabetes in subsequent pregnancies;
and

(ii)

to prevent the
development of type 2 diabetes in women with a history of gestational diabetes,
and its complications in the practice settings of the health care
providers.

(5)

Report

Not later than 4 years after the date of
the enactment of this section, the Secretary shall prepare and submit to the
Congress a report concerning the results of the demonstration projects
conducted through the grants awarded under this subsection.

(6)

Definition of
Eligible Entity

In this subsection, the term eligible
entity means a nonprofit organization (such as a nonprofit academic
center or community health center) or a State, tribal, or local health
agency.

(7)

Authorization of
Appropriations

There is authorized to be appropriated to carry
out this subsection$5,000,000 for each of fiscal years 2014 through
2018.

(d)

Postpartum
follow-Up regarding gestational diabetes

The Secretary, acting
through the Director of the Centers for Disease Control and Prevention, shall
work with the State- and tribal-based diabetes prevention and control programs
assisted by the Centers to encourage postpartum follow-up after gestational
diabetes, as medically appropriate, for the purpose of reducing the incidence
of gestational diabetes, the recurrence of gestational diabetes in subsequent
pregnancies, the development of type 2 diabetes in women with a history of
gestational diabetes, and related
complications.